Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate CRISPR Therapeutics AG before investing. In this article, we go over a few key ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA ...

By identifying and activating a master epigenetic switch using CRISPR, the researchers showed they can turn on many naturally suppressed genes from one parent to compensate for defects in the same ...

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Advancements in high-throughput CRISPR technology have accelerated the discovery of potential therapeutic targets in immune cells and cancer cells. This provides a novel insight into identifying ...

Now, new preclinical research presents the discovery and engineering of NanoCas—an ultracompact CRISPR nuclease capable of extending CRISPR’s reach in vivo beyond liver targets. NanoCas is the ...

1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5900 USA 2Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical ...

One of the founders of CRISPR Therapeutics is Emmanuel Charpentier, the discoverer of CRISPR–Cas9 and the Nobel prize of Chemistry in 2020 for that discovery. So it is safe to assume that the company ...

The discovery of the CRISPR/Cas9 gene editing tool won two researchers, Emmanuelle Charpentier and Jennifer A. Doudna, the Nobel Prize in Chemistry in 2020. Exa-cel, also called Casgevy ...

CRISPR technology, widely used in biomedical research and increasingly tested for clinical applications, relies on Cas enzymes. While Cas9 has been the predominant enzyme in CRISPR applications ...